Novelna Inc.
Novelna Inc. is a proteomics-based liquid biopsy startup dedicated to transforming cancer diagnostics through innovative, accurate, and affordable early disease detection technologies. Their mission is to ensure early disease detection is accessible to all, leveraging advanced proteomics and AI-enabled platforms to develop highly sensitive and specific diagnostic tests for cancer and other diseases. With a focus on early detection, Novelna aims to improve health outcomes globally by making diagnostics more accessible, precise, and cost-effective.
Industries
Nr. of Employees
small (1-50)
Novelna Inc.
Products
Proteomic multi-cancer early detection test (sex-specific small-protein panel)
A plasma protein-based diagnostic panel using a sex-specific set of approximately 10 proteins designed to detect multiple early-stage solid tumors with reported high sensitivity and specificity in a proof-of-concept study.
Pipeline of blood- and urine-based diagnostic panels
A portfolio of blood- and urine-based proteomic diagnostic panels at varying stages of development optimized for early-stage disease detection.
Proteomic multi-cancer early detection test (sex-specific small-protein panel)
A plasma protein-based diagnostic panel using a sex-specific set of approximately 10 proteins designed to detect multiple early-stage solid tumors with reported high sensitivity and specificity in a proof-of-concept study.
Pipeline of blood- and urine-based diagnostic panels
A portfolio of blood- and urine-based proteomic diagnostic panels at varying stages of development optimized for early-stage disease detection.
Services
Rapid identification and clinical validation of protein biomarkers using a multi-disease discovery design and independent cohort validation workflows.
Rapid identification and clinical validation of protein biomarkers using a multi-disease discovery design and independent cohort validation workflows.
Expertise Areas
- Proteomics-based biomarker discovery
- Multi-cancer early detection
- Plasma and urine diagnostic panel development
- Machine learning for diagnostic classification
Key Technologies
- Plasma proteomics
- Urine proteomics
- Proximity extension assays
- Machine learning classification models
News & Updates
A webinar discussing the integration of cutting-edge technologies into diagnostic practices, focusing on making these tools accessible to underserved populations.
Announcement of Nader Gamini's appointment as COO, highlighting his extensive experience in biotech and semiconductor industries.
Announcement of new advisors joining the board to accelerate product development and market positioning.
Announcement of a novel sex-specific protein panel test capable of detecting 18 early-stage cancers, published in BMJ Oncology.
An article discussing novel proteomics approaches that improve early disease detection over traditional methods.
Coverage of Novelna's advancements in early cancer detection technologies.
A webinar discussing the integration of cutting-edge technologies into diagnostic practices, focusing on making these tools accessible to underserved populations.
Announcement of Nader Gamini's appointment as COO, highlighting his extensive experience in biotech and semiconductor industries.
Announcement of new advisors joining the board to accelerate product development and market positioning.
Announcement of a novel sex-specific protein panel test capable of detecting 18 early-stage cancers, published in BMJ Oncology.
An article discussing novel proteomics approaches that improve early disease detection over traditional methods.
Coverage of Novelna's advancements in early cancer detection technologies.